BiotechTube

LHA510 ophthalmic suspension + LHA510 vehicle + Ranibizumab ophthalmic solution

Phase 2Completed
0 views this week 0 watching💤 Quiet
Interest: 35/100
35
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Exudative Age-Related Macular Degeneration

Conditions

Exudative Age-Related Macular Degeneration

Trial Timeline

Mar 3, 2015 → Oct 18, 2016

NCT ID
NCT02355028

About LHA510 ophthalmic suspension + LHA510 vehicle + Ranibizumab ophthalmic solution

LHA510 ophthalmic suspension + LHA510 vehicle + Ranibizumab ophthalmic solution is a phase 2 stage product being developed by Novartis for Exudative Age-Related Macular Degeneration. The current trial status is completed. This product is registered under clinical trial identifier NCT02355028. Target conditions include Exudative Age-Related Macular Degeneration.

What happened to similar drugs?

5 of 5 similar drugs in Exudative Age-Related Macular Degeneration were approved

Approved (5) Terminated (0) Active (0)
✅ranibizumabNovartisApproved
✅ranibizumabNovartisApproved
✅AfliberceptRegeneron PharmaceuticalsApproved
✅afliberceptBayerApproved
✅Vascular endothelial growth factor trap-eyeBayerApproved

Hype Score Breakdown

Clinical
12
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT02355028Phase 2Completed

Competing Products

5 competing products in Exudative Age-Related Macular Degeneration

See all competitors
ProductCompanyStageHype Score
ranibizumabNovartisApproved
43
ranibizumabNovartisApproved
39
AfliberceptRegeneron PharmaceuticalsApproved
43
afliberceptBayerApproved
40
Vascular endothelial growth factor trap-eyeBayerApproved
40